Search in:

Advanced search

mAbs Volume 3, 2011 - Issue 2

Submit an article Journal homepage

Open access

1,684

Views

CrossRef citations to date

Altmetric

Meeting Report

6^th Annual European Antibody Congress 2010

November 29–December 1, 2010, Geneva, Switzerland

Alain Beck Physico-Chemistry Department; Centre d'Immunologie Pierre Fabre; Saint Julien en Genevois, FranceCorrespondence[email protected] [email protected] [email protected]

Thierry Wurch Physico-Chemistry Department; Centre d'Immunologie Pierre Fabre; Saint Julien en Genevois, FranceCorrespondence[email protected] [email protected] [email protected]

Pages 111-132 | Received 11 Jan 2010, Accepted 11 Jan 2011, Published online: 01 Mar 2011

Cite this article
https://doi.org/10.4161/mabs.3.2.14788

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Beck A, Hanala S, Reichert JM. 4th European Antibody Congress 2008: December 1–3, 2008. mAbs 2009; 1:Switzerland Geneva 93 - 103
Google Scholar
Beck A, Reichert JM, Wurch T. 5th European Antibody Congress 2009: November 30–December 2, 2009. mAbs 2010; 2:108 - 128
PubMedGoogle Scholar
Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 352
PubMed Web of Science ®Google Scholar
Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009; 392:145 - 154
PubMed Web of Science ®Google Scholar
Beck A, Cochet O, Wurch T. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Discov 2010; 5:95 - 111
PubMed Web of Science ®Google Scholar
Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329 - 339
PubMed Web of Science ®Google Scholar
Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25:1369 - 1372
PubMed Web of Science ®Google Scholar
Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685 - 691
PubMed Web of Science ®Google Scholar
Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206 - 16215
PubMed Web of Science ®Google Scholar
Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 2008; 283:16194 - 16205
PubMed Web of Science ®Google Scholar
Wang Q, Lacher NA, Muralidhara BK, Schlittler MR, Aykent S, Demarest CW. Rapid and refined separation of human IgG2 disulfide isomers using superficially porous particles. J Sep Sci 2010; 33:2671 - 2680
PubMed Web of Science ®Google Scholar
He Y, Lacher NA, Hou W, Wang Q, Isele C, Starkey J, et al. Analysis of identity, charge variants and disulfide isomers of monoclonal antibodies with capillary zone electrophoresis in an uncoated capillary column. Anal Chem 2010; 82:3222 - 3230
PubMed Web of Science ®Google Scholar
Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010; 14:520 - 528
PubMed Web of Science ®Google Scholar
Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68:3863 - 3872
PubMed Web of Science ®Google Scholar
Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. mAbs 2009; 1:254 - 267
PubMed Web of Science ®Google Scholar
Wang X, Singh SK, Kumar S. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res 2010; 27:1512 - 1529
PubMed Web of Science ®Google Scholar
Correia IR. Stability of IgG isotypes in serum. mAbs 2010; 2:221 - 232
PubMed Web of Science ®Google Scholar
Ouellette D, Alessandri L, Piparia R, Aikhoje A, Chin A, Radziejewski C, et al. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem 2009; 389:107 - 117
PubMed Web of Science ®Google Scholar
Ouellette D, Alessandri L, Chin A, Grinnell C, Tarcsa E, Radziejewski C, et al. Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule. Anal Biochem 2010; 397:37 - 47
PubMed Web of Science ®Google Scholar
Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385 - 392
PubMed Web of Science ®Google Scholar
Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203 - 1207
PubMed Web of Science ®Google Scholar
Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70:1595 - 1605
PubMed Web of Science ®Google Scholar
Smith KGC, Clatworthy MR. FcGRIIb and the regulation of autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10:328 - 343
PubMed Web of Science ®Google Scholar
Obungu VH, Gelfanova V, Rathnachalam R, Bailey A, Sloan-Lancaster J, Huang L. Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling. Biochemistry 2009; 48:7251 - 7260
PubMed Web of Science ®Google Scholar

References

Reichert JM. Antibody-based therapeutics to watch in 2011. mAbs 2011; 3:76 - 99
PubMed Web of Science ®Google Scholar
Mazumdar S, Greenwald D. Golimumab. mAbs 2009; 1:422 - 431
PubMed Web of Science ®Google Scholar
Dhimolea E. Canakinumab. mAbs 2010; 2:3 - 13
PubMed Web of Science ®Google Scholar
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 4402
PubMed Web of Science ®Google Scholar
Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptoralpha. Cancer Immun 2007; 7:1 - 8
PubMedGoogle Scholar
Amstrong DK, Bicher A, Coleman RL, Gibbon DG, Glenn D, Old L, et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor-alpha, in platinum-sensitive ovarian cancer first relapse (Abstract). J Clinical Oncol 2008; 26:5500
PubMed Web of Science ®Google Scholar
Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7:109 - 115
PubMedGoogle Scholar
Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, et al. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma and immune cells. Clin Cancer Res 2010; 16:1191 - 1205
PubMed Web of Science ®Google Scholar
Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464:1052 - 1057
PubMed Web of Science ®Google Scholar
Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 251
PubMed Web of Science ®Google Scholar
Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010; 5:9106
PubMed Web of Science ®Google Scholar
Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458:206 - 210
PubMed Web of Science ®Google Scholar
Brennan FR, Dill Morton L, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity testing of monoclonal antibodies. mAbs 2010; 2:1 - 23
PubMedGoogle Scholar
Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The Minimum Anticipated Biological Effect Level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 2009; 20:1 - 8
PubMed Web of Science ®Google Scholar
Anand A, Assudani D, Nair P, Krishnamurthy S, Deodhar S, Arumugam M, et al. Safety, efficacy and pharmacokinetics of T1 h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis—Results from a randomized phase II trial (Abstract). J Immunol 2010; 184:96
Web of Science ®Google Scholar

References

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 3473
PubMed Web of Science ®Google Scholar
Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239 - 1249
PubMed Web of Science ®Google Scholar
Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390 - 2399
PubMed Web of Science ®Google Scholar
Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373 - 376
PubMed Web of Science ®Google Scholar
Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512 - 520
PubMed Web of Science ®Google Scholar
Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen M, et al. Human IgG2 antibodies display disulfide mediated structural isoforms. J Biol Chem 2008; 283:16194 - 16205
PubMed Web of Science ®Google Scholar
Martinez T, Guo A, Allen MJ, Han M, Pace D, Jones J, et al. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 2008; 47:7496 - 7508
PubMed Web of Science ®Google Scholar
Dillon TM, Ricci MS, Vezina C, Flynn G, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206 - 16215
PubMed Web of Science ®Google Scholar
van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554 - 1557
PubMed Web of Science ®Google Scholar
Valliere-Douglass JF, Eakin CM, Wallace A, Ketchem RR, Wang W, Treuheit MJ, et al. Glutamine-linked and non-consensus asparagine-linked oligosaccharides present in human recombinant antibodies define novel protein glycosylation motifs. J Biol Chem 2010; 285:16012 - 16022
PubMed Web of Science ®Google Scholar
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812 - 1821
PubMed Web of Science ®Google Scholar
Subramanian R, Meares CF. Bifunctional chelating agents for radiometal-labeled monoclonal antibodies. Cancer Treat Res 1990; 51:183 - 199
PubMedGoogle Scholar
Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. J Nucl Med 2003; 44:2000 - 2018
PubMed Web of Science ®Google Scholar
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453 - 2463
PubMed Web of Science ®Google Scholar
Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5:98 - 101
PubMedGoogle Scholar
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336 - 4342
PubMed Web of Science ®Google Scholar
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793 - 3803
PubMed Web of Science ®Google Scholar
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262 - 3269
PubMed Web of Science ®Google Scholar
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156 - 5164
PubMed Web of Science ®Google Scholar
Chatal JF, Davodeau F, Cherel M, Barbet J. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther 2009; 5:36 - 40
PubMed Web of Science ®Google Scholar
Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 2008; 60:1371 - 1382
PubMed Web of Science ®Google Scholar
Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, et al. Antibodies against metal chelates. Nature 1985; 316:265 - 268
PubMed Web of Science ®Google Scholar
Goodwin DA, Meares CF, David GF, McTigue M, McCall MJ, Frincke JM, et al. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int J Rad Appl Instrum B 1986; 13:383 - 391
PubMedGoogle Scholar
Goodwin DA, Mears CF, McTigue M, David GS. Monoclonal antibody hapten radiopharmaceutical delivery. Nucl Med Commun 1986; 7:569 - 580
PubMed Web of Science ®Google Scholar
Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29:226 - 234
PubMed Web of Science ®Google Scholar
Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 2008; 60:1407 - 1420
PubMed Web of Science ®Google Scholar
Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001; 19:435 - 450
PubMed Web of Science ®Google Scholar
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24:823 - 834
PubMed Web of Science ®Google Scholar
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006; 47:247 - 255
PubMed Web of Science ®Google Scholar
Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 1999; 5:3190 - 3198
PubMed Web of Science ®Google Scholar
Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24:1705 - 1711
PubMed Web of Science ®Google Scholar
Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159 - 163
PubMed Web of Science ®Google Scholar
Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549 - 557
PubMed Web of Science ®Google Scholar
Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, et al. Stable IgG-like bispecific antibodies directed towards the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703 - 4717
PubMed Web of Science ®Google Scholar
Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009; 1:128 - 141
PubMed Web of Science ®Google Scholar
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290 - 1297
PubMed Web of Science ®Google Scholar
Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. mAbs 2009; 1:339 - 347
PubMed Web of Science ®Google Scholar
Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, et al. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 2010; 299:130 - 136
PubMed Web of Science ®Google Scholar
Dieterich HJ, Kraft D, Sirtl C, Laubenthal H, Schimetta W, Pölz W, et al. Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth Analg 1998; 86:1123 - 1126
PubMed Web of Science ®Google Scholar
Wilson MR, Goddard ME, O'Dea KP, Choudhury S, Takata M. Differential roles of p55 and p75 tumor necrosis factor receptors on stretch-induced pulmonary edema in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:60 - 68
PubMed Web of Science ®Google Scholar
Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995; 374:168 - 173
PubMed Web of Science ®Google Scholar
Nuttall SD, Krishnan UV, Doughty L, Pearson K, Ryan MT, Hoogenraad NJ, et al. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur J Biochem 2003; 270:3543 - 3554
PubMedGoogle Scholar
Johnson G, Wu TT. Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunol 1998; 10:1801 - 1805
PubMed Web of Science ®Google Scholar
Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004; 55:187 - 197
PubMed Web of Science ®Google Scholar
Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci USA 2004; 101:12444 - 12449
PubMed Web of Science ®Google Scholar
Dooley H, Flajnik MF, Porter AJ. Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 2003; 40:25 - 33
PubMed Web of Science ®Google Scholar
Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogneic drugs. Curr Vasc Pharmacol 2010; 8:102 - 113
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

6^th Annual European Antibody Congress 2010

November 29–December 1, 2010, Geneva, Switzerland

References

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

6th Annual European Antibody Congress 2010

November 29–December 1, 2010, Geneva, Switzerland

References

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

6^th Annual European Antibody Congress 2010